James P. Boylan - Oct 27, 2023 Form 4 Insider Report for Immunome Inc. (IMNM)

Role
Director
Signature
/s/ Sandra G. Stoneman, Attorney-in-fact
Stock symbol
IMNM
Transactions as of
Oct 27, 2023
Transactions value $
$0
Form type
4
Date filed
10/31/2023, 06:32 PM
Previous filing
Oct 12, 2023
Next filing
Mar 11, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IMNM Stock option (right to buy) Award $0 +41.5K $0.00 41.5K Oct 27, 2023 Common Stock 41.5K $8.73 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Mr. Boylan waived the initial grant provided for under the Company's non-employee director compensation policy in effect on the date he joined the Company's board of directors pending the adoption of an amended and restated non-employee director compensation policy (the "New NED Compensation Policy"). On October 27, 2023, the compensation committee of the Company's board of directors adopted and approved the New NED Compensation Policy. The above reflects Mr. Boylan's initial grant under the New NED Compensation Policy.
F2 The options vest in 12 quarterly installments over three years, commencing on October 2, 2023 and continuing thereafter on the same day of each succeeding fiscal quarter, subject to continued service with the Company on each respective vesting date.
F3 Mr. Boylan has agreed to receive and hold for the benefit of Enavate Sciences, LP, any securities granted to him for his service as a director on the Company's board of directors. As such, Mr. Boylan disclaims beneficial ownership of, and all right, title and interest in, the reported securities.